Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 391748, 11 pages
http://dx.doi.org/10.1155/2015/391748
Research Article

Effects of Tetrahydrocurcumin on Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor Expression in Cervical Cancer Cell-Induced Angiogenesis in Nude Mice

1Division of Physiology, Faculty of Medicine, Thammasat University, Rangsit Campus, Pathumthani 12120, Thailand
2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
3Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
4Division of Physical Science, Faculty of Science and Technology, Huachiew Chalermprakiet University, Samut Prakan 10540, Thailand

Received 21 December 2014; Revised 24 January 2015; Accepted 26 January 2015

Academic Editor: Weibo Cai

Copyright © 2015 Bhornprom Yoysungnoen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. H. Maxwell, M. S. Wlesener, G.-W. Chang et al., “The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis,” Nature, vol. 399, no. 6733, pp. 271–275, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. B.-H. Jiang, F. Agani, A. Passaniti, and G. L. Semenza, “V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression,” Cancer Research, vol. 57, no. 23, pp. 5328–5335, 1997. View at Google Scholar · View at Scopus
  3. R. S. Kerbel, “Tumor angiogenesis,” The New England Journal of Medicine, vol. 358, no. 19, pp. 2039–2049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Ferrara, “Vascular endothelial growth factor: molecular and biological aspects,” Current Topics in Microbiology and Immunology, vol. 237, pp. 1–30, 1999. View at Google Scholar · View at Scopus
  5. P. Carmeliet, “Angiogenesis in health and disease,” Nature Medicine, vol. 9, no. 6, pp. 653–660, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. L. Semenza, “Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy,” Trends in Pharmacological Sciences, vol. 33, no. 4, pp. 207–214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. W.-F. Cheng, C.-A. Chen, C.-N. Lee, L.-H. Wei, F.-J. Hsieh, and C.-Y. Hsieh, “Vascular endothelial growth factor and prognosis of cervical carcinoma,” Obstetrics & Gynecology, vol. 96, no. 5, pp. 721–726, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M.-H. Kim, S.-S. Seo, Y.-S. Song et al., “Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes,” Gynecologic Oncology, vol. 90, no. 1, pp. 83–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Yoysungnoen-Chintana, P. Bhattarakosol, and S. Patumraj, “Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice,” BioMed Research International, vol. 2014, Article ID 817972, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Shibuya, S. Yamaguchi, A. Yamane et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family,” Oncogene, vol. 5, no. 4, pp. 519–524, 1990. View at Google Scholar · View at Scopus
  11. B. I. Terman, M. Dougher-Vermazen, M. E. Carrion et al., “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor,” Biochemical and Biophysical Research Communications, vol. 187, no. 3, pp. 1579–1586, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Ferrara, “Role of vascular endothelial growth factor in regulation of physiological angiogenesis,” American Journal of Physiology—Cell Physiology, vol. 280, no. 6, pp. C1358–C1366, 2001. View at Google Scholar · View at Scopus
  13. R. D. Meyer and N. Rahimi, “Comparative structure-function analysis of VEGFR-1 and VEGFR-2: what have we learned from chimeric systems?” Annals of the New York Academy of Sciences, vol. 995, pp. 200–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. H.-S. Kim, B.-R. Yi, K.-A. Hwang, S. U. Kim, and K.-C. Choi, “Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells,” Molecules and Cells, vol. 36, no. 4, pp. 347–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M.-H. Pan, T.-M. Huang, and J.-K. Lin, “Biotransformation of curcumin through reduction and glucuronidation in mice,” Drug Metabolism and Disposition, vol. 27, no. 4, pp. 486–494, 1999. View at Google Scholar · View at Scopus
  16. P. Yoysungnoen, P. Wirachwong, C. Changtam, A. Suksamram, and S. Patumraj, “Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice,” World Journal of Gastroenterology, vol. 14, no. 13, pp. 2003–2009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Mahasiripanth, S. Hokputsa, S. Niruthisard, P. Bhattarakosol, and S. Patumraj, “Effects of Acanthus ebracteatus Vahl on tumor angiogenesis and on tumor growth in nude mice implanted with cervical cancer,” Cancer Management and Research, vol. 4, no. 1, pp. 269–279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, “Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma,” The New England Journal of Medicine, vol. 324, no. 1, pp. 1–8, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Kolev, H. Uetake, S. Iida, T. Ishikawa, T. Kawano, and K. Sugihara, “Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma,” Annals of Surgical Oncology, vol. 14, no. 10, pp. 2738–2747, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Ferrara, “Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications,” Seminars in Oncology, vol. 29, no. 6, pp. 10–14, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. C. Lee, P. Rouhi, L. D. Jensen et al., “Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 46, pp. 19485–19490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. Pradeep, E. S. Sunila, and G. Kuttan, “Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies,” Integrative Cancer Therapies, vol. 4, no. 4, pp. 315–321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. Forsythe, B.-H. Jiang, N. V. Iyer et al., “Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1,” Molecular and Cellular Biology, vol. 16, no. 9, pp. 4604–4613, 1996. View at Google Scholar · View at Scopus
  24. R. D. Meyer, A. Singh, F. Majnoun, C. Latz, K. Lashkari, and N. Rahimi, “Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation,” Oncogene, vol. 23, no. 32, pp. 5523–5531, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Shibuya, “Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer,” Genes and Cancer, vol. 1, no. 11, pp. 1119–1123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Shibuya, “Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases,” Journal of Biochemistry, vol. 153, no. 1, pp. 13–19, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Shibuya, “Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies,” Genes and Cancer, vol. 2, no. 12, pp. 1097–1105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Boehm, J. Folkman, T. Browder, and M. S. O'Reilly, “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance,” Nature, vol. 390, no. 6658, pp. 404–407, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Yodkeeree, S. Garbisa, and P. Limtrakul, “Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA,” Acta Pharmacologica Sinica, vol. 29, no. 7, pp. 853–860, 2008. View at Publisher · View at Google Scholar · View at Scopus